Oxford Biomedica receives £53.5m injection from Novo Holdings
Novo Holdings invests £53.5m in Oxford Biomedica, funds which the company will use to further develop its LentiVector platform for cell and gene therapies.
Archives for May 30, 2019
Iovance builds gene therapy manufacturing facility in Philadelphia
Iovance amps up clinical and commercial immunotherapy production with a $75m (€67.3m), 136,000 square-foot build in Philadelphia’s Navy Yard.
Harbour BioMed inks agreement for ‘next generation biologic discovery’
Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.